Applied Therapeutics eyes galactosemia submission based on biomarker data

Applied Therapeutics believes it can submit an NDA for its lead program to FDA based on new biomarker data from a Phase I/II trial, citing 2018 draft guidance from the

Read the full 305 word article

User Sign In